Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 2/20 | 0.44 |
| ▸ | CNR1 | P21554 | 2/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.44 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL927349 | 1.00 | CYP3A4 (0.46) | CYP3A4CNR2CNR1FFAR1FFAR4 | |
| SCHEMBL928867 | 0.99 | CYP3A4 (0.47) | CYP3A4CNR2CNR1FFAR1FFAR4 | |
| SCHEMBL3166149 | 0.94 | CYP3A4 (0.51) | CYP3A4CNR2CNR1PRSS1PRSS2 | |
| SCHEMBL17200765 | 0.94 | CYP3A4 (0.51) | CYP3A4CNR2CNR1PRSS1PRSS2 | |
| SCHEMBL27705782 | 0.93 | CYP3A4 (0.53) | CYP3A4CNR2CNR1PRSS1PRSS2 | |
| SCHEMBL2845775 | 0.90 | CYP3A4 (0.53) | CYP3A4CNR2CNR1PRSS1PRSS2 | |
| SCHEMBL809344 | 0.88 | CYP3A4 (0.58) | CYP3A4CNR2CNR1PRSS1PRSS2 | |
| SCHEMBL689630 | 0.88 | CYP3A4 (0.58) | CYP3A4CNR2CNR1PRSS1PRSS2 | |
| SCHEMBL688275 | 0.88 | CYP3A4 (0.58) | CYP3A4CNR2CNR1PRSS1PRSS2 | |
| SCHEMBL689823 | 0.87 | CYP3A4 (0.59) | CYP3A4CNR2CNR1PRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222446-B2 | Method for producing dihydroxybenzene derivative | MITSUI CHEMICALS, INC. (JP) | 2012-07-17 | — | — | US | disclosed |
| US-20110004013-A1 | METHOD FOR PRODUCING DIHYDROXYBENZENE DERIVATIVE | MITSUI CHEMICALS, INC. (JP) | 2011-01-06 | — | — | US | disclosed |
| EP-2269976-A1 | PROCESS FOR PRODUCING DIHYDROXYBENZENE DERIVATIVE | Mitsui Chemicals, Inc. (JP) | 2011-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110004013-A1 | METHOD FOR PRODUCING DIHYDROXYBENZENE DERIVATIVE | UBE2B, UBE2G2, TUBB2B | CYP3A4 227/4885CNR2 1610/4885CNR1 2409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.